ConductScience.org, home

Paper40148484

Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.

Canelo-Vilaseca M and 6 others. Bone Marrow Transplant, 2025. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma. Papers, record 40148484. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40148484

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.
PubMed
Journal
Bone Marrow Transplant
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
6.92, provisional
iCite
Revised in PubMed
2025-05-11
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Canelo-Vilaseca MMarta
2Sabbah MMohamad
3Di Blasi RRoberta
4Cristinelli CCaterina
5Sureda AAnnahttps://orcid.org/0000-0002-1238-6970
6Caillat-Zucman SSophiehttps://orcid.org/0000-0002-4535-3550
7Thieblemont CCatherinehttps://orcid.org/0000-0002-9941-2448

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptors, Chimeric AntigenMajor topic
Immunotherapy, AdoptiveMajor topic
Lymphocyte DepletionMajor topic
LymphomaMajor topic
Humans
Cyclophosphamide
Hematopoietic Stem Cell Transplantation

Source PubMed

Download CSV of topics

References88

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116203864Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.J Exp Med2005https://conductscience.org/library/papers/16203864PubMed
230518502Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol2019https://conductscience.org/library/papers/30518502PubMed
335690221Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.Ann Oncol2022https://conductscience.org/library/papers/35690221PubMed
436122385Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.Blood2022https://conductscience.org/library/papers/36122385PubMed
53305705The stable and permanent expansion of functional T lymphocytes in athymic nude rats after a single injection of mature T cells.J Immunol1987https://conductscience.org/library/papers/3305705PubMed
634923107
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
Ann Oncol2022https://conductscience.org/library/papers/34923107PubMed
735940526Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery.Transplant Cell Ther2022https://conductscience.org/library/papers/35940526PubMed
829385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
928774879Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood2017https://conductscience.org/library/papers/28774879PubMed
1036059523Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.Front Immunol2022https://conductscience.org/library/papers/36059523PubMed
1130919158Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.Curr Oncol Rep2019https://conductscience.org/library/papers/30919158PubMed
1234799485Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.Am J Surg Pathol2022https://conductscience.org/library/papers/34799485PubMed
1335156195In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.Clin Pharmacol Ther2022https://conductscience.org/library/papers/35156195PubMed
1412242449Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.Science2002https://conductscience.org/library/papers/12242449PubMed
1524914142Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.Blood2014https://conductscience.org/library/papers/24914142PubMed
1638187393Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.Front Immunol2023https://conductscience.org/library/papers/38187393PubMed
1730809033Early and late hematologic toxicity following CD19 CAR-T cells.Bone Marrow Transplant2019https://conductscience.org/library/papers/30809033PubMed
1832888407Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet2020https://conductscience.org/library/papers/32888407PubMed
1928408462Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.Blood2017https://conductscience.org/library/papers/28408462PubMed
2037668287Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.Am J Hematol2023https://conductscience.org/library/papers/37668287PubMed

See all 88 referencesDownload CSV of references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
42969556Bendamustine induces peripheral lymphodepletion in dogs with relapsed lymphoma.J Vet Intern Med2026https://conductscience.org/library/papers/42969556PubMed
42921052When, Where, and How Much: Toward Smarter Design and Delivery of CAR T‑Cell Therapy.ACS Bio Med Chem Au2026https://conductscience.org/library/papers/42921052PubMed
42482101TCM-derived immunometabolic modulators as systems adjuvants for CAR-T therapy in solid tumors: evidence hierarchy and translational roadmap.J Transl Med2026https://conductscience.org/library/papers/42482101PubMed
42432811iPSC-Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice.Cell Prolif2026https://conductscience.org/library/papers/42432811PubMed
42411850Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/42411850PubMed
42355450B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis.Life (Basel)2026https://conductscience.org/library/papers/42355450PubMed
42245651Designing universal T cell therapies: strategies to evade natural killer cells.Front Immunol2026https://conductscience.org/library/papers/42245651PubMed
42158862Cytokine release syndrome after allogeneic hematopoietic stem cell transplantation using posttransplant cyclophosphamide: current understanding and management.Front Immunol2026https://conductscience.org/library/papers/42158862PubMed
41978748Combining Small-Molecular Compounds With CAR T-Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy.Cancer Innov2026https://conductscience.org/library/papers/41978748PubMed
41893014From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma.J Pers Med2026https://conductscience.org/library/papers/41893014PubMed
41817579The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy.Cancer Res2026https://conductscience.org/library/papers/41817579PubMed
41799502Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.Oncol Res2026https://conductscience.org/library/papers/41799502PubMed
41793185Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41793185PubMed
41792262Progress in the development of cytokine armoured CAR T cells.Nat Rev Immunol2026https://conductscience.org/library/papers/41792262PubMed
41659486Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and in vivo CAR T-cell engineering.bioRxiv2026https://conductscience.org/library/papers/41659486PubMed
41471106Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy.Pharmaceutics2025https://conductscience.org/library/papers/41471106PubMed
41280924Precision medicine with car cells in acute myeloid leukemia: where are we?Front Immunol2025https://conductscience.org/library/papers/41280924PubMed
41279526Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells.bioRxiv2025https://conductscience.org/library/papers/41279526PubMed
41250215In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies.Exp Hematol Oncol2025https://conductscience.org/library/papers/41250215PubMed
41052891Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective.RMD Open2025https://conductscience.org/library/papers/41052891PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40148484

GET https://conductscience.org/api/papers/v1/40148484/references?page=2